Arxis, Inc. Class A Common Stock (ARXS)vsLockheed Martin Corporation (LMT)
ARXS
Arxis, Inc. Class A Common Stock
$48.98
+15.33%
INDUSTRIALS · Cap: $17.14B
LMT
Lockheed Martin Corporation
$573.75
+0.86%
INDUSTRIALS · Cap: $118.59B
Smart Verdict
WallStSmart Research — data-driven comparison
Lockheed Martin Corporation generates 4398% more annual revenue ($75.11B vs $1.67B). LMT leads profitability with a 6.4% profit margin vs 6.2%. LMT trades at a lower P/E of 24.9x. LMT earns a higher WallStSmart Score of 55/100 (C-).
ARXS
Hold38
out of 100
Grade: F
LMT
Buy55
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ARXS.
Margin of Safety
-69.8%
Fair Value
$342.36
Current Price
$573.75
$231.39 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 24.2%
Revenue surging 20.7% year-over-year
Every $100 of equity generates 72 in profit
Large-cap with strong market position
Generating 2.9B in free cash flow
Areas to Watch
0.0% earnings growth
6.2% margin — thin
Premium valuation, high expectations priced in
ROE of -1.6% — below average capital efficiency
Trading at 17.6x book value
0.3% revenue growth
6.4% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ARXS
The strongest argument for ARXS centers on Operating Margin, Revenue Growth. Revenue growth of 20.7% demonstrates continued momentum.
Bull Case : LMT
The strongest argument for LMT centers on Return on Equity, Market Cap, Free Cash Flow. PEG of 1.07 suggests the stock is reasonably priced for its growth.
Bear Case : ARXS
The primary concerns for ARXS are EPS Growth, Profit Margin, P/E Ratio. A P/E of 2088.5x leaves little room for execution misses.
Bear Case : LMT
The primary concerns for LMT are Price/Book, Revenue Growth, Profit Margin. Debt-to-equity of 2.34 is elevated, increasing financial risk.
Key Dynamics to Monitor
ARXS profiles as a growth stock while LMT is a value play — different risk/reward profiles.
ARXS is growing revenue faster at 20.7% — sustainability is the question.
LMT generates stronger free cash flow (2.9B), providing more financial flexibility.
Monitor AEROSPACE & DEFENSE industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LMT scores higher overall (55/100 vs 38/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Arxis, Inc. Class A Common Stock
INDUSTRIALS · AEROSPACE & DEFENSE · USA
Arxis, Inc. (ARXS) is a dynamic biotechnology company focused on developing cutting-edge therapeutics for complex diseases, leveraging a robust research and development framework. With a diverse drug pipeline targeting both rare and widespread conditions, Arxis emphasizes strategic partnerships and comprehensive clinical initiatives to drive innovation and improve patient outcomes. As it progresses through critical clinical trial phases, the company is well-positioned for substantial growth and value creation, making it an attractive proposition for institutional investors in the fast-evolving biotech sector.
Lockheed Martin Corporation
INDUSTRIALS · AEROSPACE & DEFENSE · USA
Lockheed Martin Corporation is an American aerospace, defense, information security, and technology company with worldwide interests. It is headquartered in North Bethesda, Maryland, in the Washington, D.C., area.
Visit Website →Compare with Other AEROSPACE & DEFENSE Stocks
Want to dig deeper into these stocks?